PACB (Pacific Biosciences of California) Moat Score: 5/10 (As of Jun. 28, 2026)


PACB Pacific Biosciences of California Inc PACB
53 GF Score
Price $1.65
GF Value $1.62
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Moat Score?

Pacific Biosciences of California PACB +3.12% 53 Moat Score is 5 as of Jun. 28, 2026. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 8 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Pacific Biosciences of California ranks better than 91.15% on this metric.

Pacific Biosciences of California has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Pacific Biosciences of California has Narrow Moat: Pacific Biosciences has a solid narrow moat due to its valuable intellectual property and patents in the genomics space. The company benefits from customer switching costs and consistent innovation in R&D. However, it faces strong competition, limiting its market leadership and pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pacific Biosciences of California might have Narrow Moat - Solid narrow moat.

Pacific Biosciences of California  (NAS:PACB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pacific Biosciences of California Moat Score Related Terms

PACB vs CATX, LAB, KIDS: Moat Score Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Moat Score distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Moat Score falls into.


PACB
53GF Score
Pacific Biosciences of California Inc PACB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Pacific Biosciences of California (PACB) has a Moat Score of 5 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pacific Biosciences of California ranks #75 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Pacific Biosciences of California's Moat Score too high?
Pacific Biosciences of California's current Moat Score is 5. Based on the distribution chart, Pacific Biosciences of California ranks #75 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Moat Score compare to CATX and LAB?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #75 out of 847 companies for Moat Score. This places Pacific Biosciences of California in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Pacific Biosciences of California's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.65 — trading 1.9% above its estimated fair value. The current Moat Score is 5. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Moat Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued. The current stock price of $1.65 is trading 1.9% above its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

  • Moat Score: 5
  • GF Value™: $1.62 vs. price of $1.65 (1.9% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score

Get the complete analysis for PACB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$1.62
GF Value